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Asthma is often difficult to control and it is likely that not all patients are optimally treated.
This study aimed to explore asthma control in adults receiving fixed dose combination (FDC)
therapy. Control of asthma was assessed using the mannitol challenge test as a monitoring tool
to see if this would give additional information compared to the asthma control test (ACT). The
study was an open-label, prospective study on 98 adults prescribed with FDC therapies for at
least three months.
74 patients considered that their asthma was well controlled. However, 60 patients had a
positive mannitol challenge test (PD15 < 635 mg), and when those with a positive response
to the short-acting b2-agonist (15%) after the mannitol challenge test were included, this
increased to 64 patients (65%). Exploratory analysis determined that the spirometry parame-
ters; FEV1/FVC and FEV1% of predicted, were statistically significant predictors of a positive
mannitol challenge test. Co-morbid conditions such as concomitant upper airway involvement
or eczema did not predict mannitol reactivity.
Although most patients rated their asthma as well controlled, many provided a positive
mannitol challenge test, suggesting the presence of underlying inflammation, despite treat-
ment with fixed dose combination therapy.ospital of Lund, Department of Respiratory Medicine and Allergology, Lund, Sweden. Tel.: þ46 (0) 708
. Romberg).
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Asthma is one of the most common chronic diseases in
Sweden with a prevalence of about 8% in the adult popu-
lation [1]. The strategy for treating asthma depends on
what level of disease the patients have. A common medi-
cation for treating asthma is a fixed dose combination (FDC)
of an inhaled corticosteroid with a long acting b2-agonist.
The FDC’s available at the time of the study were bude-
sonide/formoterol (Symbicort, AstraZeneca), fluticasone/
salmeterol (Seretide, GlaxoSmithKline) and beclometa-
sone/formoterol (Innovair, Chiesi).
Achieving and managing good control over asthma is
difficult. Adherence to therapy is a recognized problem.
Moreover, it is clear that spirometry and lung function tests
are not sufficient objective methodologies for the detec-
tion of uncontrolled disease with ongoing inflammation in
the entire part of the lower airways. Here we tested the
hypothesis that not all asthma patients are optimally
treated.
In the present study, we explored the prevalence of
optimally treated asthma patients in primary care consec-
utively attending at a single site in Sweden. Several
different strategies were employed to evaluate the degree
of clinical control over the asthma of real-life patients.
These included spirometry, symptom questionnaires and a
bronchial provocation test (mannitol challenge test). The
mannitol challenge test is an indirect assessment that re-
flects ongoing disease in asthma with the added advantage
that it provides information on disease activity and can be
used to guide treatment decisions [2].Methods
Study design and patient population
This was an open-label study conducted at one primary care
site in Sweden. The main objective of the study was to
evaluate the real-life effectiveness of FDC asthma therapy.
To participate in the study, patients had to have a previ-
ously verified asthma diagnosis, aged 18e65 years, and
been prescribed any FDC therapy available on a regular
basis for at least three months and were not allowed to
have taken oral corticosteroids within the 28 days leading
up to the study. Enrolled patients were required to have a
forced expiratory volume in the first second (FEV1) of at
least 70% of the predicted value according to the recom-
mendations in the Summary of Product Characteristics
(SmPC) for mannitol. Patients with other respiratory or
obstructive disease, including recent infection or exacer-
bation, were excluded from the study.
Consecutive patients, attending their appointments at
the primary care site, were enrolled at a first visit forevaluating eligibility according the inclusion criteria.
Eligible patients were asked to continue with their usual
asthma medication until the second visit, which was up to 4
weeks later. However, the patient’s normal FDC asthma
therapy was to be withheld in the morning of visit 2. This
was due to the observational study design, which was
designed not to interfere with the patient’s ordinary
medication except during the day of the test. At the second
visit the inclusion criteria had to be confirmed again before
the asthma control test (ACT) and mannitol challenge test
were performed. After the mannitol challenge test a
reversibility test was performed. Following asthma evalu-
ation, the patient’s usual asthma therapy was continued as
normal.
All patients provided written informed consent before
participation. The study was approved by a local Ethics
Committee and was conducted in accordance with the In-
ternational Conference on Harmonization legislation of
Good Clinical Practice (ICH GCP), the declaration of Hel-
sinki, and all applicable regulatory requirements.
Asthma assessments
The ACT is an advocated tool to estimate clinical control
[3]. The asthma severity of each participant was assessed
two-fold: (1) Patients rated their own disease-control in the
ACT; (2) The Investigator rated the frequency of symptoms
experienced each week. The ACT was rated on a scale of
0e25, where scores of 20e25 signified good asthma control
(well-treated) and scores below 20 indicated that the pa-
tient felt symptomatic.
Asthma severity was assessed by evaluating the medi-
cation each patient was prescribed by their usual physician.
The Investigator also classified the frequency of symptoms
experienced by the patient as A: No symptoms; B: Symp-
toms 1e2 times per week; C: Symptoms 3e6 times per week
and D: Daily symptoms.
Mannitol challenge and reversibility tests
Oral mannitol inhalation powder (Aridol/Osmohale) is a
well-characterized indirect bronchial challenge test suit-
able for use in a primary-care setting [4]. It is also stan-
dardized, reproducible and correlate to the degree of
inflammation in the airways. The mannitol challenge test
was performed by step-wise administering the mannitol dry
powder by inhalation in increasing doses (0, 5, 10, 20, 40,
80, 160, 160 and 160 mg mannitol with cumulative doses of
0, 5, 15, 35, 75, 155, 315, 475 and 635 mg mannitol in total
at each administration). A direct positive test was defined
as the cumulative dose 635 mg inducing a drop in FEV by
15% (PD15 FEV). Between each dose, the bronchial
hyperresponsiveness of each patient was measured by
spirometry. The challenge test was positive if the FEV1 fell
Table 1 Patient demographics.
Variable Total (n Z 98)
Gender
Male 37 (37.8%)
Female 61 (62.2%)
Age (in years) 41.9 (18.1; 62.9)
Height (in cm) 170.5 (153; 193)
Weight (in kg) 77.6 (48.0; 126.4)
Forced vital capacity (in L) 4.08 (1.97; 6.81)
FEV1 Max of Pre-dose
and Dose 1 (0 mg) (in L)
3.20 (1.70; 5.86)
FEV1% (as FEV1/FVC) 76.0 (55.0; 95.0)
FEV1% of predicted 95.5 (71.0; 128.0)
All variables are presented as median (min, max), except for
gender, which is presented as n(%).
FEV1: forced expiratory volume in 1 s; FVC: forced vital ca-
pacity.
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tween two consecutive doses [5].
After mannitol provocation, a new spirometry according
ATS/ERS guidelines was conducted 15 min after inhalation
of a short-acting b2-agonist (terbutaline, 0.5 mg  2, or
salbutamol, 0.2 mg  4). This procedure expedited recov-
ery of the patients and detected those that may have had a
negative response on the mannitol challenge test, but still
obtained a reversibility of 15% from the last dose of
mannitol. These patients were also classified as positive in
this study.
Safety assessments
Adverse events (AEs) were recorded for the duration of the
study and classified by system organ class and preferred
term using MedDRA version 11. Vital signs, including dia-
stolic blood pressure, systolic blood pressure and pulse
rate, and physical examinations were performed before
initiating of any study procedures.
Statistical methods and analyses
The changes in FEV1 were analyzed using the Wilcoxon
Signed Rank test. Exploratory analyses for univariable and
multivariable prediction of a positive outcome from the
mannitol test was performed and presented with the odds
ratio (OR), 95% confidence intervals (CI) and area under the
receiver operating characteristics curve (ROC-AUC) were
calculated with associated p-values. All baseline variables
were used as possible independent predictors in the uni-
variable logistic regression model. Only statistically signif-
icant independent predictors from these analyses were part
of the selected multivariable logistic model. The best
model was selected based on the highest AUC statistics.
One patient was excluded from the exploratory analyses as
she had not taken FDC for the desired full 3 months prior to
study initiation, but was included in the ACT and mannitol
challenge tests.
Exploratory analysis of provocative dose for a fall in FEV1
of 15% from baseline (PD15) was performed for all positive
patients. For each patient PD15 was calculated according
to equation (1), where the slope is the beta coefficient
obtained for each patient individually from the linear
regression, with FEV1 over time as the dependent variable
and the cumulative dose as the independent variable.
PD15Zð0:85)Baseline FEV1  Baseline FEV1Þ=slope ð1Þ
Results
Patient disposition
Out of 108 patients who fulfilled the inclusion criteria at the
first visit, 98 participated in the study. Ten patients did not
fulfill the inclusion criteria (nZ 5: too old, FEV1 below 70%
of predicted, not on regular FDC at visit 2, respiratory
infection and uncontrolled hypertension, not able to attend
the second visit during the study period (nZ 4), withdrawn
consent (nZ 1)). All patients were treated with FDC in drypowder inhalers with an inhaled corticoid steroid (ICS) dose
range of 160e1000 mg daily.
Ninety-eight patients participated in the study: 37 male
(38%) and 61 female (62%). Study participants were be-
tween the ages of 18 and 62 years old (median age of 42
years), with median height of 170.5 cm and median weight
of 77.6 kg (Table 1). Excluding asthma, the most common
co-morbid conditions were: symptoms of the upper airways
(allergic rhinoconjunctivitis with or without nasal polyps),
atopic dermatitis and psychiatric diseases (anxiety,
depression, panic disorder, sleep disorder, social phobia)
(Table 2).
Asthma control tests and asthma scores
Overall, patients considered that their asthma was well
treated, producing a median ACT score of 22 out of 25
(range: 9e25). 74 patients (75.5%) of the study participants
contributed a high ACT score (20e25) indicating that their
asthma was well controlled, while only 24 patients (24.5%)
classified their asthma as symptomatic, providing an ACT
score of less than 20.
The frequency of the asthma symptoms were recorded
and assigned to a category by the Investigator; 33 patients
reported no symptoms, 49 patients had symptoms 1e2 days
per week, 14 patients had symptoms 3e6 days per week
and 2 patients had symptoms every day (Fig. 1).
Mannitol challenge and reversibility tests
The FEV1 of 60 patients fell by at least 15% from baseline, or
10% between consecutive doses, during the mannitol chal-
lenge test (Table 3). These patients were considered to
have had a direct positive test.
Out of all 60 patients with a direct positive test to
mannitol, 49 also had a positive reversibility test defined
as an improvement in FEV1 of at least 15% from the last
dose of mannitol. An additional four patients had a
negative direct test but reversed 15%. These patients
were also considered to have had a positive outcome, i.e.
Table 2 Incidence of predictor by outcome.
Variable Total
Negative
(n Z 34)
Positive
(n Z 64)
BMI Median (min, max) 25.6 (20.2; 36.8) 24.5
(16.6; 45.5)
Asthma Control Test (assessed by patient)
Median (min, max) 22.5 (9.0; 25.0) 22.0
(12.0; 25.0)
Symptomatic
(0e19) [n(%)]
9 (26.5%) 15 (23.4%)
Well-treated
(20e25) [n(%)]
25 (73.5%) 49 (76.6%)
FEV1 Median (min, max)
FEV1 (L) Pre-dose 3.37 (1.70; 5.86) 3.03
(1.83; 5.37)
FEV1% (FEV1/FVC) 80.0 (70.0; 95.0) 74.5
(55.0; 93.0)
FEV1% of predicted 102.0
(73.0; 128.0)
92.5
(71.0; 118.0)
Selected medical history [n(%)]
Symptoms of
the upper airways
26 (76.5%) 54 (84.4%)
Atopic dermatitis 8 (23.5%) 6 (9.4%)
Psychiatric disorders 5 (14.7%) 8 (12.5%)
BMI: body mass index; FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity.
Note: Symptoms of the upper airways includes nasal polyps,
rhinitis allergic and rhinoconjunctivitis allergic; atopic derma-
titis includes dermatitis atopic and eczema; psychiatric disor-
ders includes anxiety, depression, panic disorder, sleep disorder
and social phobia.
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tients were categorized as having a positive outcome in
the mannitol challenge test, with or without the revers-
ibility test (Table 3, Fig. 2).Figure 1 Asthma control test and asthma severity scores. (A)
Asthma control test where the scores 0e19 represent symp-
tomatic asthma and the scores 20e25 represent well-treated
asthma. (B) Asthma score for the severity of asthma where A
is no symptoms, B is symptoms 1e2 days/week, C is symptoms
3e6 days per week and D is daily symptoms.Exploratory analyses
Examination revealed that FEV1 maximum of pre-dose and
dose 1, FEV1/FVC and FEV1% of predicted were statistically
significant (p < 0.05) observed predictors of a positive
mannitol challenge test (Table 4). Gender (p Z 0.96), age
(pZ 0.72), height (pZ 0.57), weight (pZ 0.88) and forced
vital capacity (pZ 0.45) were not significant (p > 0.05) and
therefore were not good predictors. Symptoms of the upper
airways did not differ in the prediction of a positive or
negative mannitol challenge test, but there was a
discrepancy for atopic dermatitis (Table 2).
The statistically significant predictors with the highest
ROC-AUC values were used in multivariable logistic
regression for prediction of a positive result in the mannitol
challenge test. FEV1/FVC and FEV1% of predicted had the
highest ROC-AUC values of 0.71 and 0.68, respectively.
Following multivariable logistic regression analysis, FEV1/
FVC and FEV1% of predicted were both statistically signifi-
cant (p Z 0.0088 and 0.0319, respectively, Table 4).
The mean PD15 of patients with bronchial hyper-
responsiveness was 376 mg mannitol. The range of PD15
varied greatly between patients from 6 mg to 635 mg
mannitol powder (Fig. 3). In order to elucidate the severity
of individuals’ disease, this wide range of doses of mannitol
was sub-categorized into mild (>155 mg), moderate
(>35 mg to 155 mg) or severe (35 mg) bronchial hyper-
responsiveness [6]. The majority of patients with a positive
outcome in the mannitol challenge test were classified as
having mild bronchial hyperresponsiveness (43 patients,
67%). Approximately a quarter of patients were categorized
as having moderate bronchial hyperresponsiveness (17 pa-
tients, 27%), and 4 patients (6%) had severe bronchial
hyperresponsiveness. However, no statistically significant
relationship between the ACT and bronchial hyper-
responsiveness could be demonstrated.
Safety analyses
No SAEs were reported and no AEs led to premature
termination of the test. The test procedure was well
tolerated by all patients with only 13 patients reporting
mild discomfort (such as throat irritation and cough). The
most commonly reported AE, experienced by 9 patients,
was ‘no therapeutic response’; a lack of immediate rescue
by the short-acting bronchodilator that was given post-
challenge.
Discussion
This study evaluated the real-life effectiveness of FDC
therapies for asthma patients using the mannitol challenge
test and asthma control assessments. The main finding of
the present study demonstrates that a large fraction of
patients prescribed FDC asthma medication by their usual
physician were reactive to mannitol, indicating uncon-
trolled underlying disease.
Of the enrolled patients, the majority (76.3%) consid-
ered that their asthma was well controlled (ACT score 20)
and all of them were prescribed medication for moderate
to severe asthma by their usual physician. However, the
Table 3 Asthma assessments.
Variable N Z 98
Mannitol direct positive þ reversible
Negative [n(%)] 34 (34.7%)
Positive [n(%)] 64 (65.3%)
95% CI 55.0%e74.6%
Mannitol direct positive
Negative [n(%)] 38 (38.8%)
Positive [n(%)] 60 (61.2%)
95% CI 50.8%e70.9%
Reversibility test positive
Negative [n(%)] 49 (50.0%)
Positive [n(%)] 49 (50.0%)
95% CI 39.7%e60.3%
Asthma control test
Median (Min; Max) 22.0 (9.0; 25.0)
Symptomatic (0e19) [n(%)] 24 (24.5%)
Well-controlled (20e25) [n(%)] 74 (75.5%)
CI: confidence interval.
Figure 3 Change in forced expiratory volume in 1 s (FEV1)
versus accumulated mannitol dose by patient and outcome.
Individual patients FEV1 scores for (A) a negative primary
outcome and (B) a positive primary outcome.
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1e2 times per week, suggesting that the patients them-
selves over-estimated their own asthma control.
Low ACT scores are thought to indicate uncontrolled
inflammation in the lower airways, however the ACT is not
without its draw-backs. The perception and self-
assessment of a person’s disease is subjective and incon-
sistent. Subtle subconscious adjustments of the patient to
the disease may effectively reduce symptoms without
actually increasing the disease control. Moreover,
although the majority of patients rated their asthma as
well-controlled, there was no difference between the ACT
scores of those patients with a positive mannitol challenge
test and those with a negative outcome. When the ACT
scores were analyzed by outcome of the mannitol chal-
lenge test, the median ACT scores were 22.0 out of 25 forFigure 2 Results of the mannitol challenge and reversibility
tests.patients with a positive outcome and 22.5 out of 25 for
patients with a negative outcome. In addition, a similar
fraction of patients rated their asthma as well-controlled
between the groups: 76.6% of patients with a positive
outcome and 73.5% of patients with a negative outcome
(Table 4). Interestingly, when the mannitol challenge test
results were presented to the patient, many admitted low
adherence to therapy, and another common reflection
was that they had adjusted their daily activity in order to
avoid symptoms.
Mannitol is in contrast to the more commonly used
metacholine; an indirect test that exhibits its action by
osmotic stimuli in the lower airways and mediates its
effect by secondary immune mechanisms. Thus, hyper-
responsiveness to mannitol is likely to reflect ongoing
inflammation in the lower airways. Standard evaluation of
the mannitol challenge test results include PD15 with an
accumulated maximum dose of 635 mg mannitol. In a pre-
vious study, we have shown that additional information may
be achieved by evaluating the degree of variability/
reversibility to a short acting b2-agonist after challenge [7].
In 101 swimmers, we found evidence of more problematic
asthma in those who displayed reversibility (15% FEV1)
Table 4 Predictors of a positive mannitol challenge test.
Predictor Odds ratio
(95% CI)
P value ROC-Auc
(95% CI)
Univariable logistic
regression
FEV1 maximum of
pre-dose and
dose 1 (0 mg)
0.60
(0.36e0.99)
0.0437 0.64
(0.52e0.75)
FEV1% (FEV1/FVC) 0.90
(0.84e0.96)
0.0009 0.71
(0.61e0.82)
FEV1% of predicted 0.95
(0.92e0.98)
0.0023 0.68
(0.57e0.79)
Multivariable
logistic regression
FEV1% (FEV1/FVC) 0.91
(0.85e0.98)
0.0088 e
FEV1% of predicted 0.96
(0.93e1.00)
0.0319 e
CI: confidence interval; FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity; ROC-AUC: under the receiver oper-
ating characteristics curve.
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of a positive mannitol challenge test [7]. In the present
study, half the patients had a positive reversibility test
after the mannitol challenge test and three patients were
reversible and PD15 negative. In all, 65 out of 98 patients
(65%) had a positive mannitol challenge test including the
reversibility test. Overall, these results indicate a presence
of underlying inflammation despite treatment with FDC
therapy.
The most probable reason for why symptoms of the
upper airways did not differ in the prediction of a positive
or negative mannitol challenge test is that patients treating
themselves with over the counter products and not
reporting them as pharmaceuticals in the same way.
Furthermore, out of all the patients, only 3 were smokers; 2
of which were regular smokers (<15 pack years and one
<10 pack years), however, no smoking was permitted dur-
ing the day of the test and this is unlikely to affect the
overall results. Gender, age, vital signs, height, weight,
BMI, forced vital capacity and FEV1 at pre-dose also did not
predict mannitol reactivity.
There were nine patients who did not respond to a
normal dose of short-acting b2-agonist at the reversibility
test, and an increased dose had to be given. This may be
due to a down-regulation of the b2-receptors due to
inflammation [8].
A weakness of the present study might be that it is a
single site study. However, this can also be seen as a
strength since all patients were handled in a similar way,
which may not always be the case in a multi-center study.
It would have been a strength if FeNO and an ordinary
spirometry with a reversibility test would have been eval-
uated before the mannitol provocation. One of the biggest
strengths in this study is the high number of consecutive
ordinary patients, attending one primary care site for their
ordinary asthma controls for an extended evaluation of
their asthma.It is important for the healthcare system to continuously
evaluate different treatments. This study was performed in
a controlled manner and suggests that, although most pa-
tients rated their asthma as well controlled, many provided
a positive mannitol challenge test, which may indicate the
presence of underlying inflammation despite treatment
with FDC therapy. Therefore, many patients treated with
an FDC are still not optimally treated. Thus, these data
invite discussion and a possible reconsideration of the
treatment strategy.
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